Spyre Therapeutics, Inc.
SYRE
Classement en actions
#2313
Spyre Therapeutics, Inc. is a biotechnology firm operating at the preclinical... Spyre Therapeutics, Inc. is a biotechnology firm operating at the preclinical stage, dedicated to creating innovative treatments for individuals afflicted with inflammatory bowel disease (IBD). Among its pipeline candidates is SPY001, a human monoclonal immunoglobulin G1 antibody specifically engineered to target and bind with the a4ß7 integrin. This particular therapy is under development for addressing both ulcerative colitis and Crohn's disease, two forms of IBD. Furthermore, Spyre Therapeutics is advancing SPY002, another human monoclonal antibody that aims to interact with tumor necrosis factor-like ligand 1A (TL1A). A synergistic approach is also being explored with SPY120, a compound that merges the anti-a4ß7 action of SPY001 with the anti-TL1A activity of SPY002. All these programs are currently undergoing preclinical evaluation. Beyond these, the company's early-stage portfolio encompasses several additional promising candidates: SPY003, an anti-IL-23 monoclonal antibody; SPY004, a monoclonal antibody with a novel mechanism of action; SPY130, which combines anti-a4ß7 and anti-IL-23 antibodies; and SPY230, a dual antibody therapy featuring anti-TL1A and anti-IL-23 components. Originally incorporated in 2013, the organization was previously known as Aeglea BioTherapeutics, Inc., before rebranding to Spyre Therapeutics, Inc. in November 2023. Its headquarters are located in Waltham, Massachusetts.
Prix de l'action
$93.11
Capitalisation boursière
$8.59B
Changement (1 jour)
1.87%
Changement (1 an)
300.47%
Pays
US
Échange Spyre Therapeutics, Inc. (SYRE)
Catégorie
Healthcare
Revenus pour Spyre Therapeutics, Inc. (SYRE)
Revenus en Jun 2026 TTM : $90.49M
Selon les derniers rapports financiers de Spyre Therapeutics, Inc., le chiffre d'affaires actuel de l'entreprise (TTM) est de $90.49M. En 2023, l'entreprise a réalisé un chiffre d'affaires de $886.00K une diminution par rapport à le chiffre d'affaires de l'année 2022, qui était de $2.33M. Le chiffre d'affaires correspond au revenu total généré par la vente de biens ou de services. Contrairement au bénéfice, aucune dépense n'est déduite.
Historique des revenus pour Spyre Therapeutics, Inc. de 2014 à 2026
Revenus à la fin de chaque année
| Année | Revenus | Changez |
|---|---|---|
| 2026 (TTM) | $90.49M | 0.00% |
| 2024 | 0.00 | -100.00% |
| 2023 | $886.00K | -61.96% |
| 2022 | $2.33M | -87.57% |
| 2021 | $18.74M | 0.00% |
| 2020 | 0.00 | 0.00% |
| 2019 | 0.00 | -100.00% |
| 2018 | $3.89M | -25.30% |
| 2017 | $5.21M | 12.47% |
| 2016 | $4.63M | -23.94% |
| 2015 | $6.09M | 0.00% |
| 2014 | 0.00 | 0.00% |
Revenus d’entreprises similaires ou concurrentes
| Entreprise | Revenus | Différence de revenus | Pays |
|---|---|---|---|
| $12.62B | 13,850.43% |
US
|
|
| $2.23B | 2,362.04% |
US
|
|
| $15.74B | 17,298.20% |
AU
|
|
| $6.02B | 6,553.80% |
NL
|
|
| - | - |
CH
|
